Cabinet approves continuation of National AIDS Control Programme till 2020
New Delhi: The Cabinet Committee on Economic Affairs chaired by the Prime Minister has given its approval for continuation of National AIDS Control Programme-IV (NACP-IV) beyond 12th Five Year Plan for a period of three years from April 2017 to March 2020. The total outlay will be Rs.6434.76 crore.The program will have the following benefits More than 99% of the population will be kept...
Login or Register to read the full article
New Delhi: The Cabinet Committee on Economic Affairs chaired by the Prime Minister has given its approval for continuation of National AIDS Control Programme-IV (NACP-IV) beyond 12th Five Year Plan for a period of three years from April 2017 to March 2020. The total outlay will be Rs.6434.76 crore.
The program will have the following benefits
- More than 99% of the population will be kept HIV free.
- More than 70 lakh of the key population covered annually through a comprehensive HIV prevention programme.
- Around 15 crore of the vulnerable population (including five crore pregnant women) will be tested for HIV in three years of the project.
- Two crores 32 lakh units of blood will be collected at NACO’s supported blood banks during the three years of the project.
- Two crores 82 lakh episodes of sexually transmitted infections will be managed under project during three years of the project.
- Seventeen lakh of PLHIV will be put on free anti-retroviral treatment by the end of the project period.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd